THE UNIVERSITY OF MICHIGAN Comprehensive Cancer Center and Trovagene Inc. initiated a collaborative research program focused on the Trovera KRAS ctDNA liquid biopsy test in pancreatic cancer. “KRAS gene mutations occur in over 90 percent of pancreatic carcinomas. There is an urgent need for targeted therapies and a precision diagnostic test to identify who would...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
